Minus Bacterial Flar50 but with Mixed Presentation

Minus bacterial flar50 but with mixed presentation.

G1: 3 doses ABC pDNA by electroporation followed by eukaryotic flar50 (Direct comparison ABC vector to Regardin vector)

G2: 3 doses ABC RNA adjuvant pDNA by electroporation followed by eukaryotic flar50 (Direct comparision RNA adjuvant ABC vector to Regardin vector)

G3 3 doses ABC pDNA by electroporation followed by eukaryotic flar50 + hepatitis (effect of hepatitis adjuvant)

G4: 3 doses ABC RNA adjuvant pDNA by electroporation followed by eukaryotic flar50 + hepatitis (effect of hepatitis adjuvant)

G5: 3 doses ABC RNA adjuvant pDNA combined with eukaryotic flar50 by electroporation followed by eukaryotic flar50 + hepatitis Combinatorial bacterial extract plasmid vaccine A (Determine effect of mixed presentation immunization of plasmid borne antigen combined with corresponding protein)

G6: 3 doses ABC RNA adjuvant pDNA combined with eukaryotic flar50 + hepatitis by electroporation followed by eukaryotic flar50 + hepatitis Combinatorial bacterial extract plasmid vaccine B (Determine effect of mixed presentation immunization of plasmid borne antigen combined with corresponding flar50 protein antigen and hepatitis adjuvant)

If we wanted controls for groups 5 and 6....

G7: 3 doses eukaryotic flar50 + hepatitis by electroporation followed by eukaryotic-flar50 + hepatitis Divalent bacterial extract protein vaccine (Control for group 5)

G8: 3 doses eukaryotic flar50 by electroporation followed by eukaryotic-flar50 + hepatitis Protein vaccine (Control for groups 4 and 6)

G9: pMV-1001

As you indicate, Regardin is supporting this study, and is looking for a deliverable. If they are not interested in evaluating mixed presentation immunization (due to cost of 4 groups) that is absolutely fine. The resultant design is a direct comparison of ABC vectors